Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 1
https://www.gamida-cell.com/wp-content/uploads/TCT_2021_horw...

Phase 3 results above.

As a general rule is a study like this best avoided? They are not measuring survivability, but "Time to neutrophil engraftment"

The market responded well to the report, as the stock is up 70% after hours.

Survivability seemed to be their secondary end point.
Secondary Endpoint: Days Alive and Out of the Hospital
in the First 100 Days Post-Transplant (ITT Population)
Omidubicel: Median 60.5 days
Control: Median 48.0 days
p = 0.005

Disease-free and Overall Survival
(ITT population)
This does not seem very impressive to me.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.